Nine-valent human papilloma virus vaccine preparation and application thereof

• Main Authors: GAO JUN, YANG ZENGMIN, ZHANG HAIJIANG, YIN FEI, JIANG XULIN, ZHANG CHUNYAN, YU HONGYANG, LIU YUYING, WU SHUMING, YANG XIUFEN, CHEN DAN, ZHANG YAO, GAO WENSHUANG, ZHANG RUIXIA, CHEN XIAO, LIU YONGJIANG, WANG YAN
• Format: Patent
• Language: Chinese; English
• Published: 24.05.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MEDICAL OR VETERINARY SCIENCE; NANOTECHNOLOGY; PERFORMING OPERATIONS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; TRANSPORTING

The invention relates to the field of biological medicine, and particularly discloses a vaccine preparation of a nine-valent human papilloma virus and application of the vaccine preparation. The nine-valent human papilloma virus vaccine preparation comprises HPV6, 11, 16, 18, 31, 33, 45, 52 and 58 type truncated L1-VLP protein antigens subjected to maturation treatment, an adjuvant, a histidine buffer system, an osmotic regulator and a surfactant. The antigen components in the nine-valent HPV vaccine preparation provided by the invention all come from the main capsid protein L1 of HPV and are truncated, and through the truncated L1 protein expressed by an escherichia coli system, the yield of the L1 protein is improved, and the production cost of the vaccine is reduced. By optimizing a buffer system and combining maturing post-treatment in the preparation process of various types of VLP antigens, the obtained nine-valent HPV vaccine preparation induces high-level immune response. 本发明涉及生物医药领域，具体公开一种九价人乳头瘤病毒的疫苗